Literature DB >> 19467718

Antibodies against interferon-beta in multiple sclerosis.

Nina Karin Aarskog1, Tove Marøy, Kjell-Morten Myhr, Christian A Vedeler.   

Abstract

We measured the frequency of binding antibody (BAB) and neutralizing antibody (NAB) against interferon-beta (IFN-beta) in sera from 827 patients with relapsing-remitting multiple sclerosis (RRMS) using various IFN-beta medications. Of the 827 patients, 363 (43.9%) had serum BAB after more than 12 months of IFN-beta treatment. Of the 363 BAB-positive sera, we analyzed 137 for BAB using a myxovirus-resistant protein A (MxA) protein induction assay (ELISA) and an MxA messenger RNA (mRNA) induction assay (real-time polymerase chain reaction (PCR)). We obtained similar results for each serum in both NAB assays, indicating a good correlation between transcription and translation of MxA. We tested all 363 sera by real-time PCR, and NAB was present in 70.8% of BAB-positive sera, or 31.1% of the 827 patients with relapsing-remitting multiple sclerosis (RRMS). Real-time PCR offers several advantages for measuring NAB compared with the MxA protein induction enzyme-linked immunosorbent assay and should be used routinely for NAB among patients with MS using IFN-beta treatment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19467718     DOI： 10.1016/j.jneuroim.2009.04.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  7 in total

Review 1.  Determinants of interferon β efficacy in patients with multiple sclerosis.

Authors:  Joep Killestein; Chris H Polman
Journal:  Nat Rev Neurol       Date:  2011-03-01       Impact factor: 42.937

2.  Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory.

Authors:  Melody Sauerborn; Miranda M C van Beers; Wim Jiskoot; Grzegorz M Kijanka; Louis Boon; Huub Schellekens; Vera Brinks
Journal:  J Clin Immunol       Date:  2012-09-04       Impact factor: 8.317

3.  Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.

Authors:  Meenu Wadhwa; Meena Subramanyam; Susan Goelz; Jaya Goyal; Vijay Jethwa; Wendy Jones; James G Files; Daniel Kramer; Chris Bird; Paula Dilger; Michael Tovey; Christophe Lallemand; Robin Thorpe
Journal:  J Interferon Cytokine Res       Date:  2013-07-13       Impact factor: 2.607

4.  Analyses of the pathways involved in early- and late-phase induction of IFN-beta during C. muridarum infection of oviduct epithelial cells.

Authors:  Sishun Hu; Kristen L Hosey; Wilbert A Derbigny
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

Review 5.  Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.

Authors:  Murli Krishna; Steven G Nadler
Journal:  Front Immunol       Date:  2016-02-02       Impact factor: 7.561

6.  Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.

Authors:  Sonia Gavasso; Ellen Faergestad Mosleth; Tove Marøy; Katarina Jørgensen; Hanne-Linda Nakkestad; Bjørn-Tore Gjertsen; Kjell-Morten Myhr; Christian Vedeler
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

7.  Treatment with recombinant human bone morphogenetic protein 7 leads to a transient induction of neutralizing autoantibodies in a subset of patients.

Authors:  Andrea Schuette; Arash Moghaddam; Petra Seemann; Georg N Duda; Gerhard Schmidmaier; Lutz Schomburg
Journal:  BBA Clin       Date:  2016-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.